{"id":"W4402704941","doi":"10.1016/j.annonc.2024.08.1714","title":"1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Bavarian Nordic; Merck KGaA; Pfizer; CMC Microsystems; National Cancer Institute; National Institutes of Health","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Pathology; Alternative medicine; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075393,0.001442174,0.001782511,0.0003161441,0.0003285094,0.000807654,0.0007896236,0.000751364,0.005637221],"category_scores_gemma":[0.0005516044,0.0004672276,0.001834987,0.0004381707,0.0007179279,0.0005044862,0.0004387956,0.002451358,0.001038685],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009928453,"about_ca_system_score_gemma":0.001935848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003771167,"about_ca_topic_score_gemma":0.009184303,"domain_scores_codex":[0.9997727,0.00009485618,0.000007581148,0.00004177987,0.00001950527,0.00006347254],"domain_scores_gemma":[0.9995832,0.00003853427,0.00007025571,0.00004079092,0.00002624035,0.0002409426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9173136,0.01663282,0.008901146,0.0003906321,0.002664408,0.0001469163,0.0001065796,0.001433132,0.01266995,0.0002439343,0.004855416,0.03464144],"study_design_scores_gemma":[0.7980174,0.1613272,0.03134103,0.00003804501,0.002215338,0.0001594423,0.00008725748,0.001019606,0.001734933,0.0002728981,0.003744038,0.00004284648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917399,0.001163659,0.0002461586,0.0004894429,0.0001315361,0.001025057,0.003371875,0.00006946223,0.001762841],"genre_scores_gemma":[0.9776004,0.00203367,0.001007234,0.001267761,0.0002061812,0.001676882,0.008365487,0.00005021248,0.007792139],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005637221,"threshold_uncertainty_score":0.01885843,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05670950738378817,"score_gpt":0.4136443889298662,"score_spread":0.3569348815460781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}